Drug intelligence / Profile preview

Diamaxin

Development stage: Unknown
Lead developer: ADP Pharma Corporation
Administration: Oral

Overview

**Diamaxin** is an oral consumer-health dietary-supplement brand marketed by ADP Pharma for diabetes-related nutritional support. The brand includes multiple formulations: Diamaxin 300 mg and 600 mg contain alpha-lipoic acid, while Diamaxin 50 mg and 150 mg contain alpha-lipoic acid with zinc and chromium picolinate. ADP Pharma positions the products to support blood-glucose balance and immunity and, for the higher alpha-lipoic-acid strengths, to help reduce progression of diabetes-associated neuropathy, nephropathy, and retinopathy. Alpha-lipoic acid has antioxidant activity and may support endothelial function and insulin sensitivity; chromium is intended to support insulin-mediated glucose metabolism, and zinc supports nutritional and immune functions.

Brand names: Diamaxin

Beyond the preview

Go deeper on Diamaxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diamaxin.

Explore the full profile